19. Trulicity

Trulicity is currently holding its own in sales despite competition. (Eli Lilly)

Company: Eli Lilly
2019 sales: $4.13 billion 
Projected 2026 sales: $7.43 billion 
Projected CAGR: +9%
Used for: glycemic control for Type 2 diabetes

Eli Lilly's GLP-1 diabetes fighter Trulicity has been locked in a battle for sales supremacy with Novo Nordisk's Ozempic and oral follow-up drug Rybelsus. But with a recent first-of-its-kind approval in tow, Trulicity could be well positioned to keep adding to its blockbuster sales in the coming years despite the pressure. 

Trulicity snagged $4.13 billion in 2019 sales in its fifth year on the market. With a new cardiovascular risk reduction label expansion, the drug could be set to reach $7.43 billion in sales in 2026, Evaluate Pharma predicted. 

That new CV approval could prove to be a gamechanger not only for Trulicity but also the rest of the GLP-1 class, including the fierce rivals from Novo.

RELATED: Eli Lilly's Trulicity nabs novel CV approval in patients with or without established disease

19. Trulicity

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.